Leukemia
November 6
3 min read
A chemotherapy-free front-line regimen of ponatinib plus blinatumomab significantly improved event-free survival (EFS) compared with imatinib plus chemotherapy in adults with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), a phase III study found.